Kids' CF drug levels under the microscope: new study aims to personalize dosing
NCT ID NCT07303621
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the cystic fibrosis drug combination ETI (elexacaftor-tezacaftor-ivacaftor) behaves in children aged 2 to 17. Researchers will measure drug levels in the blood and see how they relate to the drug's benefits and side effects, such as liver problems or mood changes. The goal is to better understand how to dose the drug safely and effectively in kids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Femme Mère Enfant (HFME)
RECRUITINGBron, 69029, France
Contact Phone: •••-•••-•••• Email: •••••@•••••